Information:
Fel:
ID
38800
Beskrivning
Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents; ODM derived from: https://clinicaltrials.gov/show/NCT01939496
Länk
https://clinicaltrials.gov/show/NCT01939496
Nyckelord
Versioner (1)
- 05/11/19 05/11/19 -
Rättsinnehavare
See clinicaltrials.gov
Uppladdad den
5 novembre 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Diabetes Mellitus, Type 2 NCT01939496
Eligibility Diabetes Mellitus, Type 2 NCT01939496
- StudyEvent: Eligibility
Similar models
Eligibility Diabetes Mellitus, Type 2 NCT01939496
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Diabetes Mellitus, Non-Insulin-Dependent
Item
patients with a diagnosis of type 2 diabetes mellitus
boolean
C0011860 (UMLS CUI [1])
Hypertensive disease | Sitting systolic blood pressure | Sitting diastolic blood pressure
Item
patients with hypertension (seated office sbp of >=130 mmhg and <160 mmhg and seated office dbp of >= 70 mmhg at screening and at week -2
boolean
C0020538 (UMLS CUI [1])
C1319893 (UMLS CUI [2])
C1319894 (UMLS CUI [3])
C1319893 (UMLS CUI [2])
C1319894 (UMLS CUI [3])
Antihypertensive Agents Quantity | Antihypertensive Agents Dose Stable
Item
patients on stable doses of 1 to 3 anti-hypertensive agents for at least 5 weeks before screening
boolean
C0003364 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0003364 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
C1265611 (UMLS CUI [1,2])
C0003364 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
Oral hypoglycemic Quantity | Oral hypoglycemic Dose Stable | Metformin
Item
patients on stable doses of 1 to 3 oral anti-hyperglycemic agents which must include metformin, for at least 8 weeks before screening
boolean
C0359086 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0359086 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
C0025598 (UMLS CUI [3])
C1265611 (UMLS CUI [1,2])
C0359086 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
C0025598 (UMLS CUI [3])
Diabetic Ketoacidosis
Item
a history of diabetic ketoacidosis
boolean
C0011880 (UMLS CUI [1])
Diabetes Mellitus, Insulin-Dependent
Item
type 1 diabetes mellitus (t1dm)
boolean
C0011854 (UMLS CUI [1])
Pancreas Transplantation | Beta Cell Transplantation
Item
pancreas or beta-cell transplantation
boolean
C0030275 (UMLS CUI [1])
C0030281 (UMLS CUI [2,1])
C0040732 (UMLS CUI [2,2])
C0030281 (UMLS CUI [2,1])
C0040732 (UMLS CUI [2,2])
Fasting C-peptide level
Item
fasting c-peptide <0.70 ng/ml (0.23 nmol/l)
boolean
C2208720 (UMLS CUI [1])
Body mass index
Item
body mass index <30 kg/m2
boolean
C1305855 (UMLS CUI [1])
Thyroid Disease Poorly controlled
Item
has ongoing, inadequately controlled thyroid disorder
boolean
C0040128 (UMLS CUI [1,1])
C3853134 (UMLS CUI [1,2])
C3853134 (UMLS CUI [1,2])
Cardiorenal disease Requirement Therapeutic immunosuppression
Item
has a history of cardio-renal disease that required treatment with immunosuppressive therapy.
boolean
C0155601 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0021079 (UMLS CUI [1,3])
C1514873 (UMLS CUI [1,2])
C0021079 (UMLS CUI [1,3])